Whitelab Genomics Analysis: $10M Raised
What is Whitelab Genomics?
WhiteLab Genomics builds AI tools for genomic medicine, combining biological data analysis with computational methods. Its ALFRED Platform includes proprietary modules for biomarker mapping, receptor prediction, vector engineering, and payload design. The company was founded in 2019, is backed by Y Combinator, and operates from Paris, Boston, and Montreal.
Location
8 Rue Jean Antoine de Baïf, Paris, Ile de France 75000, France
Employees
11-50
Founded
2019
Revenue
$7.4M
Business Model
Collaborative partnerships and funding for AI-driven genomic therapy development.
Product Features & Capabilities
- Gene & RNA-based therapies, Target Receptors Identification, Viral Vector Design, Non-Viral Vector Design, Payload Design, Bioproduction Optimization, Cell Therapy Pipeline.
How much Whitelab Genomics raised
1 - $10 million
September 12, 2022Lead Investor: Omnes Capital, Debiopharm
Who are the founders of Whitelab Genomics
DD
David Delbourgo
Founder
JC
Julien Cottineau
Founder
HQ Full Address
8 Rue Jean Antoine de Baïf, Paris, Ile de France 75000, France
Investors
- WhiteLab Genomics has raised $10 million in funding.
- The funding round was led by investors including:
- Alven Capital
- Bpifrance
- Eurazeo
- Kima Ventures
Market Focus
Whitelab Genomics primarily focuses on the genomic medicine industry, specifically in optimizing biological data and artificial intelligence to enhance the development of pre-clinical genomic therapies.
Competitors Overview
Whitelab Genomics operates in the genomic medicine sector, focusing on the optimization of biological data and AI for pre-clinical genomic therapies. Its main competitors include:
-
Owkin: Specializes in AI-driven drug discovery and development, particularly in oncology. Owkin's advantage lies in its strong partnerships with hospitals and research institutions, allowing for extensive clinical data utilization.
-
BenevolentAI: Focuses on using AI to accelerate drug discovery and development. Its notable advantage is its extensive database of biomedical knowledge, which enhances its predictive capabilities in identifying potential drug candidates.
-
Dyno Therapeutics: Works on optimizing adeno-associated virus (AAV) gene therapies using AI. Dyno's unique approach involves leveraging machine learning to design better viral vectors, which can improve the efficacy and safety of gene therapies.
-
Toulouse White Biotechnology (TWB): Engages in biotechnological research and development, particularly in the field of synthetic biology. TWB's advantage is its collaborative approach, working with various stakeholders in the biotech ecosystem.
-
Stilla Technologies: Develops digital PCR technology for precise nucleic acid quantification. Its competitive edge is in providing highly sensitive and reproducible results, which is crucial for genomic applications.
-
HTL Biotechnology: Focuses on the production of high-quality plasmid DNA for gene therapy and vaccine development. HTL's advantage is its expertise in plasmid manufacturing, which is essential for the success of many genomic therapies.
These competitors vary in their specific focus areas within genomic medicine, with differences in technology, partnerships, and product offerings that provide them with distinct advantages in the market.
See something that needs updating? Suggest edits to this profile.